ZBH

Business profile & competitive position

Zimmer Biomet Holdings, Inc. sits in the Healthcare sector under the Medical - Devices industry. It is a global medical technology company that designs, manufactures and markets orthopedic reconstructive products, sports medicine and biologics, extremities and trauma products, craniomaxillofacial and thoracic hardware, bone cement, surgical products, and integrated digital/robotic technologies that layer in data, analytics and artificial intelligence. Its devices treat disorders or injuries to bones, joints and supporting soft tissues, and the company works with healthcare professionals around the world to advance product innovation.

The financial signature is moderate rather than dominant. The trailing net margin is 9.5% and return on equity is 6.4%. Those figures do not suggest strong pricing power or a capital-light franchise; instead, they are consistent with an orthopedic-device model that requires heavy investment in R&D, regulatory approvals, hospital selling relationships and physical inventory. A key operating fact supporting that view is that consignment sales represented approximately 85% of net sales in 2025, meaning a large share of revenue depends on inventory that sits in hospitals or surgery centers until a procedure takes place. That model can create sticky customer relationships, but it also ties up working capital and exposes results to procedure-volume swings.

Financial posture

ZBH has a market capitalization of $18.3 billion and trades at a P/E ratio of 22.9. Profitability is reflected in the 9.5% net margin and 6.4% ROE, while the beta of 0.47 indicates the stock has historically moved less than half as much as the broad market. At the current snapshot, the price is $94.445, which sits just under the 50-day EMA of $95.57, with an RSI of 44.8.

Taken together, the valuation and risk metrics describe a large, stable medical-device operator rather than a high-growth disruptor. The P/E near 23 is neither deep-value nor aggressive for a profitable healthcare name, and the low beta fits an industry whose revenues are tied to surgical procedure demand rather than consumer or cyclical spending. The 6.4% ROE, however, is on the lower side, reinforcing that this is a business reinvesting heavily for future share rather than one currently generating standout returns on its equity base.

Strategic priorities & outlook

According to the company’s most recent SEC 10-K filing, Zimmer Biomet’s near-term operational goals center on four priorities. First, it aims to rapidly commercialize new data solutions, surgical techniques, innovative materials, biologics products, and implant and instrument designs. Second, it plans to broaden offerings in certain product categories and explore newer technologies, including artificial intelligence and machine learning. Third, it expects to continue identifying innovative technologies through acquisitions, licensing arrangements or strategic alliances. Fourth, it is executing a multi-year initiative to convert substantial portions of the U.S. sales force from independent sales agents to employees.

The filing also notes that the company’s revenue is geographically concentrated in important ways. The U.S. accounted for approximately 95% of Americas net sales and Japan accounted for approximately 50% of Asia Pacific net sales in 2025. Meanwhile, R&D staffing stood at roughly 2,000 employees worldwide as of December 31, 2025. Those details matter because they highlight both the scale of the innovation engine and the geographic revenue nodes that could move quarterly results.

Macro & geopolitical exposure

As a large-cap Medical - Devices company, Zimmer Biomet is exposed to healthcare reimbursement policy, regulatory scrutiny and surgical-procedure volumes across its three regional segments: Americas, EMEA and Asia Pacific. Currency risk is real given that Japan drives roughly half of Asia Pacific net sales and non-U.S. revenues flow back in dollars. Tariffs or duties on imported implants and instruments can affect cost structures, while changes in hospital budgets or government payer rates can alter demand for elective and reconstructive procedures.

The sector also carries product-liability and recall exposure inherent to permanently implanted medical devices, inventory risk from the consignment model, and supply-chain sensitivity for specialized metals, polymers and biologics. These are generic structural features of the orthopedic-device industry rather than company-specific forecasts, but they are the macro lenses through which results are typically judged.

Recent developments

The most recent headline flow has been valuation- and management-oriented. On September 8, 2026, gurufocus.com asked whether ZBH was a bargain after a 3.9% drop, citing the GF Value model’s undervalued reading. That same day, prnewswire.com reported that Zimmer Biomet announced Americas leadership promotions to accelerate commercial transformation. On September 10, 2026, defenseworld.net published a “Critical Contrast” comparison between Zimmer Biomet and CapsoVision. More recently, on September 17, 2026, zacks.com ran a piece titled “Here’s Why Zimmer Biomet (ZBH) is a Strong Value Stock.” None of these items reported new operational data, but they show a cluster of value-oriented commentary and internal sales-leadership changes heading into the final quarter of the fiscal year.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, ZBH has beaten the market's real expectation in 7 of 8 reports (a 100% beat rate in the convention used by the data set), with an average earnings surprise of 3.2%. The average five-day price move after earnings across those quarters is 2.57%, classified as an upward drift. On the surface, the stock appears to reward beats.

But the recent history adds an important nuance: beats have not reliably translated into follow-through. In the most recent report on August 5, 2026, ZBH posted EPS of $2.07 versus an estimate of $2.01, a 3.0% surprise, yet the next-day return was -0.99% and the stock drifted -0.28% over the following five days. The prior quarter, April 28, 2026, delivered a much larger 12.4% beat ($2.09 vs. $1.86) and still fell 3.3% the next day, though it eked out a 0.25% gain over five days. Those two episodes were offset by stronger reactions earlier in the year: the February 10, 2026 report beat by only 1.7% ($2.42 vs. $2.38) and rallied 4.61% the next day and 7.49% over five sessions, while the November 5, 2025 quarter, which beat by 1.6% ($1.90 vs. $1.87), gained 1.1% next-day and 2.83% over the next week.

The takeaway is that the positive average drift is being driven by a couple of strong quarters, not by a mechanical “beat equals pop” pattern. Heading into the November 4, 2026 report before the open, the unofficial consensus stands at $1.89 per share. Investors watching the print should therefore look not only at the beat-or-miss headline, but also at how guidance, procedure-volume commentary and currency impacts frame the reaction.

For a deeper dive into the full institutional verdict on ZBH, including consensus revisions, analyst rating distributions and forward estimates, consult the platform’s complete earnings intelligence dashboard rather than relying solely on headline numbers.